Eisai President Warns Other Industries About Pharma M&A Risks
This article was originally published in PharmAsia News
Commenting on recent acquisitions of Japanese domestic pharmaceutical companies by companies from different industries, Eisai President Haruo Naito welcomed the M&A activities as inflow of new investments to energize the industry. As the Japanese government has shown support for innovation and strengthened assistance for pharmaceutical research and development, foreign investments will be flowing in as well. But Naito also cautioned about the industrial risks. Because pharmaceutical research and development is inevitably costly and the success of a company lies in its abilities to develop and market new drugs, Naito said, no matter what industries the new entries come from, a risk-taking attitude is a must. (Click here for more - Japanese language) "President Of Eisai Haruo Naito: Pharmaceutical Development Costly" - Sankai News (3/25/08)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.